Dr. Clamon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Dr
Iowa City, IA 52242Phone+1 319-356-1932Fax+1 319-353-8377
Education & Training
- University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1976 - 1977
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1974 - 1976
- Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1971 - 1972
- Washington University in St. Louis School of MedicineClass of 1971
Certifications & Licensure
- IA State Medical License 1976 - 2024
- MO State Medical License 1974 - 2016
- WI State Medical License 1978 - 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2 Start of enrollment: 2000 Feb 01
- Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer Start of enrollment: 2000 Dec 18
Publications & Presentations
PubMed
- Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer.Margaret M Byrne, Grerk Sutamtewagul, William Zeitler, Sarah L Mott, Gideon K D Zamba
Frontiers in Oncology. 2024-01-01 - 12 citationsInflammation as a Therapeutic Target in Cancer Cachexia.Gerald Clamon, Margaret M Byrne, Erin E Talbert
Cancers. 2022-10-26 - 1 citationsA Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.Paula M Fracasso, Sherry A Goodner, Jonathan D Wildi, Michael J Naughton, Gerald P Linette
American Journal of Clinical Oncology. 2022-07-01
Grant Support
- Calgb 60301: Sorafenib For Solid Tumors And Hematologic MalignanciesNational Center For Research Resources2006
- University Of Iowa Calgb Institutional GrantNational Cancer Institute2004–2006
- Data &Safety MonitoringNational Cancer Institute2005
- Calgb 60101 Phase I Study Of OSI-774 For Solid TumorsNational Center For Research Resources2004–2005
- Calgb Institutional GrantNational Cancer Institute2003
- Univ Of Iowa Calgb Institutional GrantNational Cancer Institute1998–2002
- Cancer And Leukemia Group BNational Cancer Institute1993–1997
- University Of Iowa Institutional Calgb GrantNational Cancer Institute1988–1992
- Southeastern Cancer Study GroupNational Cancer Institute1986
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: